Terms: = Ovarian cancer AND TAL1, TCL5, 6886, ENSG00000162367, SCL, P17542, tal-1
12 results:
1. Two-phase dual-signal-readout immunosensing platform based on multifunctional carbon nano-onions for ovarian cancer biomarker detection.
Huang Y; Zhang S; Chen Y; Gao L; Dai H; Lin Y
J Mater Chem B; 2023 Aug; 11(30):7209-7216. PubMed ID: 37427755
[TBL] [Abstract] [Full Text] [Related]
2. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.
Gunaratne PH; Pan Y; Rao AK; Lin C; Hernandez-Herrera A; Liang K; Rait AS; Venkatanarayan A; Benham AL; Rubab F; Kim SS; Rajapakshe K; Chan CK; Mangala LS; Lopez-Berestein G; Sood AK; Rowat AC; Coarfa C; Pirollo KF; Flores ER; Chang EH
Cancer; 2019 Jul; 125(14):2409-2422. PubMed ID: 31012964
[TBL] [Abstract] [Full Text] [Related]
3. SF1 immunohistochemistry is useful in differentiating uterine tumours resembling sex cord-stromal tumours from potential histological mimics.
Stewart CJ; Crook M; Tan A
Pathology; 2016 Aug; 48(5):434-40. PubMed ID: 27311867
[TBL] [Abstract] [Full Text] [Related]
4. MAP17 overexpression is a common characteristic of carcinomas.
Guijarro MV; Leal JF; Fominaya J; Blanco-Aparicio C; Alonso S; Lleonart M; Castellvi J; Ruiz L; Ramon Y Cajal S; Carnero A
Carcinogenesis; 2007 Aug; 28(8):1646-52. PubMed ID: 17426052
[TBL] [Abstract] [Full Text] [Related]
5. [scleroderma-like skin changes following administration of paclitaxel for the treatment of ovarian carcinoma].
Eisenbeilss C; Weizel J; Wolff H
J Dtsch Dermatol Ges; 2003 Jun; 1(6):468-70. PubMed ID: 16295141
[TBL] [Abstract] [Full Text] [Related]
6. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.
Herter S; Piper DE; Aaron W; Gabriele T; Cutler G; Cao P; Bhatt AS; Choe Y; Craik CS; Walker N; Meininger D; Hoey T; Austin RJ
Biochem J; 2005 Aug; 390(Pt 1):125-36. PubMed ID: 15839837
[TBL] [Abstract] [Full Text] [Related]
7. Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy.
Robson M; Hensley M; Barakat R; Brown C; Chi D; Poynor E; Offit K
Gynecol Oncol; 2003 May; 89(2):281-7. PubMed ID: 12713992
[TBL] [Abstract] [Full Text] [Related]
8. Serum copper levels in carcinoma of ovary and cervix.
Saxena P; Yadav S; Salhan S; Bhowmick KT
Indian J Physiol Pharmacol; 2002 Apr; 46(2):159-66. PubMed ID: 12500490
[TBL] [Abstract] [Full Text] [Related]
9. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract] [Full Text] [Related]
10. [Systemic scleroderma and cancer. Search for predictive factors of cancer in 123 patients with scleroderma].
Kyndt X; Hebbar M; Queyrel V; Hachulla E; Hatron PY; Devulder B
Rev Med Interne; 1997 Jul; 18(7):528-32. PubMed ID: 9255370
[TBL] [Abstract] [Full Text] [Related]
11. Systemic and anti-neuronal auto-antibodies in patients with paraneoplastic neurological disease.
Moll JW; Hooijkaas H; van Goorbergh BC; Roos LG; Henzen-Logmans SC; Vecht CJ
J Neurol; 1996 Jan; 243(1):51-6. PubMed ID: 8869387
[TBL] [Abstract] [Full Text] [Related]
12. Serum copper level in ovarian carcinoma.
Margalioth EJ; Udassin R; Maor J; Schenker JG
Cancer; 1985 Aug; 56(4):856-9. PubMed ID: 2990656
[TBL] [Abstract] [Full Text] [Related]
